Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

<p>Abstract</p> <p>Background</p> <p>Many prostate cancers demonstrate an increased expression of growth factor receptors such as vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) which have been correlated with incr...

Full description

Bibliographic Details
Main Authors: Brooks Colin, Sheu Tommy, Bridges Kathleen, Mason Kathy, Kuban Deborah, Mathew Paul, Meyn Raymond
Format: Article
Language:English
Published: BMC 2012-09-01
Series:Radiation Oncology
Subjects:
Sunitinib
Combinational therapy
Targeted therapy
Prostate cancer
Tyrosine kinase inhibitor
Radiation
Online Access:http://www.ro-journal.com/content/7/1/154

Internet

http://www.ro-journal.com/content/7/1/154

Similar Items